Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.73 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | RXRA | P19793 | 3/20 | 0.37 |
| ▸ | RXRB | P28702 | 2/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4378777 | 0.86 | FOLH1 (0.77) | FOLH1PTGER1ABCB1PPARARXRA | |
| SCHEMBL4379752 | 0.85 | FOLH1 (1.00) | FOLH1PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL2058308 | 0.84 | FOLH1 (1.00) | FOLH1PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL4377997 | 0.83 | FOLH1 (0.81) | FOLH1PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL4379587 | 0.83 | FOLH1 (0.81) | FOLH1PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL4373970 | 0.83 | FOLH1 (0.81) | FOLH1PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL4380763 | 0.80 | FOLH1 (0.75) | FOLH1PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL4377625 | 0.77 | FOLH1 (1.00) | FOLH1HPGD | |
| SCHEMBL4368704 | 0.76 | FOLH1 (0.77) | FOLH1PTGER1 | |
| SCHEMBL4369851 | 0.76 | FOLH1 (0.77) | FOLH1RXRARXRBRXRGHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553866-B2 | 3-(2-Oxo-tetrahydrothiopyran-3-yl)propionic acid; inhibiting the prostrate specific antigen;angiogenesis inhibition; compulsive disorder, neuropathy, analgesics, anticarcinogenic agents; Huntinton's disease; antidiabetic agents; retinopathy; gluacoma; effecting transforming growth factor, glutamate | EISAI CORPORATION OF NORTH AMERICA (US) | 2009-06-30 | — | — | US | disclosed |
| US-20080004334-A1 | 3-(2-Oxo-tetrahydrothiopyran-3-yl)propionic acid; inhibiting the prostrate specific antigen;angiogenesis inhibition; compulsive disorder, neuropathy, analgesics, anticarcinogenic agents; Huntinton's disease; antidiabetic agents; retinopathy; gluacoma; effecting transforming growth factor, glutamate | EISAI INC. | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004334-A1 | 3-(2-Oxo-tetrahydrothiopyran-3-yl)propionic acid; inhibiting the prostrate specific antigen;angiogenesis inhibition; compulsive disorder, neuropathy, analgesics, anticarcinogenic agents; Huntinton's disease; antidiabetic agents; retinopathy; gluacoma; effecting transforming growth factor, glutamate | FOLH1, NGF, RIMKLA | FOLH1 1/4885PTGER1 265/4885PTGER4 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.